Foundation for the National Institutes of Health

Berkshire Biomedical to Present at the LSI USA '23 Emerging Medtech Summit

Retrieved on: 
Tuesday, March 14, 2023
Foundation for the National Institutes of Health, LSI, SBIR, Substance abuse, PDT, Berkshire, COPA, Patient, NIDA, FDA, National Institute on Drug Abuse, NIH, De novo, Bangladesh Technical Education Board, Pharmaceutical industry

DALLAS, March 14, 2023 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or the "Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, announced today that John Timberlake, Chief Executive Officer, will present at the fourth annual Life Science Intelligence (LSI) USA '23 Emerging Medtech Summit on March 22, 2023, at 10:55 am PDT.

Key Points: 
  • DALLAS, March 14, 2023 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or the "Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, announced today that John Timberlake, Chief Executive Officer, will present at the fourth annual Life Science Intelligence (LSI) USA '23 Emerging Medtech Summit on March 22, 2023, at 10:55 am PDT.
  • "Presenting at the LSI Emerging Medtech Summit provides an opportunity to showcase our proprietary, cloud-based, physician-enabled COPA device and the Company's initial focus on utilizing our technology to help more patients with Opioid Use Disorder gain access to take-home therapy," stated Mr. Timberlake.
  • We look forward to sharing the considerable progress the Company has made advancing the development of our COPA technology in preparation for filing a De Novo application with the FDA later this year."
  • Those attending the Emerging Medtech Summit who are interested in scheduling a one-on-one meeting with management, can utilize the meeting portal or can contact Michael Miller at [email protected] .

Hoag's Pickup Family Neurosciences Institute Selected to Participate in Revolutionary Clinical Trial for the Prevention of Alzheimer's Disease

Retrieved on: 
Thursday, March 2, 2023
Memory, Safety, Research, Ron, Weatherall Institute of Molecular Medicine, PET, University, Patient, University of California, Irvine Medical Center, Alzheimer's disease, Risk, Molecular medicine, Foundation for the National Institutes of Health, Disease, Hope, Biomarker, National Institute on Aging, Ageing, Hoag, Brain, Pharmaceutical industry, Medical imaging, Vaccine

NEWPORT BEACH, Calif., March 2, 2023 /PRNewswire/ -- Hoag's Pickup Family Neurosciences Institute has started enrolling participants for a Phase 1 clinical trial evaluating the safety and tolerability of a first-of-its-kind Alzheimer's disease vaccine. The hope is that the vaccine will eventually be used to prevent Alzheimer's disease in healthy people who are at risk.

Key Points: 
  • NEWPORT BEACH, Calif., March 2, 2023 /PRNewswire/ -- Hoag's Pickup Family Neurosciences Institute has started enrolling participants for a Phase 1 clinical trial evaluating the safety and tolerability of a first-of-its-kind Alzheimer's disease vaccine.
  • The hope is that the vaccine will eventually be used to prevent Alzheimer's disease in healthy people who are at risk.
  • Hoag is the only site in California among total six sites in the United States selected to participate in the study.
  • Hoag's Pickup Family Neurosciences Institute is currently offering many other Alzheimer's clinical trials.

Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer

Retrieved on: 
Tuesday, February 28, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Boston University, Therapy, RNA, Merck, Drug discovery, Senior, MBA, Ginkgo Bioworks, Chemistry, Drug development, Scripps Research, Acquisition, Publication, Doctor of Philosophy, Foundation for the National Institutes of Health, Bio, Research fellow, LoDo, Denver, API, Bangladesh Technical Education Board, Pharmaceutical industry, Vaccine, Zymergen, Kora (instrument)

Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer.

Key Points: 
  • Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer.
  • He is joining Korro most recently from Zymergen, following its acquisition by Ginkgo Bioworks.
  • “We are pleased that Dr. Colletti has joined the Korro team to help us advance a new class of genetic medicines to treat diseases with high prevalence with an RNA editing toolkit,” said Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President of Korro Bio.
  • He previously served as Senior Vice President of Drug Discovery R&D at Zymergen (acquired by Ginkgo Bioworks in 2022) and as Chief Scientific Officer at Lodo Therapeutics (acquired by Zymergen in 2021).

Ellodi Pharmaceuticals Welcomes Debra Silberg MD, PhD, FACG to its Board of Directors

Retrieved on: 
Monday, February 27, 2023
Biotechnology, General Health, Pharmaceutical, Health, University, American College, Molecular biology, Doctor of Philosophy, FACG, Organization, Drug development, Partnership, FDA, BS, Albert Einstein College of Medicine, Patient, NDA, University of Pennsylvania Health System, Foundation for the National Institutes of Health, NIH, Division, Gastrointestinal disease, EMA, AstraZeneca, Eosinophilic esophagitis, Wayne State University School of Medicine, Medication, TPG Inc., American College of Gastroenterology, Bangladesh Technical Education Board, Physician, Pharmaceutical industry, MD, Gastroenterology, Takeda, Immunology

Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company dedicated to the continued development of APT-1011, a novel, investigational oral therapy for the treatment of Eosinophilic Esophagitis (EoE), announced today that Debra Silberg, MD, PhD, FACG has joined the company’s board of directors.

Key Points: 
  • Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company dedicated to the continued development of APT-1011, a novel, investigational oral therapy for the treatment of Eosinophilic Esophagitis (EoE), announced today that Debra Silberg, MD, PhD, FACG has joined the company’s board of directors.
  • Dr. Silberg is an accomplished life sciences executive with deep experience across all stages of drug development.
  • “This is an exciting time to be joining the Ellodi board," said Dr. Silberg.
  • The board will continue to provide guidance on the ongoing strategic direction of Ellodi Pharmaceuticals as it works towards the completion and commercialization of the APT-1011 development program.

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Retrieved on: 
Thursday, January 5, 2023
Johns Hopkins School of Medicine, Clinical trial, Diabetic nephropathy, Diabetes, Ulcerative colitis, Steroid, Partnering, Multiple sclerosis, LANCL2, Telephone number (mathematics), MS, Research, Non-alcoholic fatty liver disease, Lupus, Eosinophilic esophagitis, NASH, Psoriasis, Atopic dermatitis, Neurology, Moa, NLRX1, Alzheimer's disease, Disease, Gastroenterology, Rheumatoid arthritis, CNS, Absorption, Patient, Chronic obstructive pulmonary disease, Degenerative disease, RA, Safety, Foundation for the National Institutes of Health, Webcast, SLE, Conference, UC, Race, Endoscopy, International, Pharmaceutical industry, Vaccine, MD, Asthma

Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;

Key Points: 
  • Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;
    NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a comprehensive update on its future clinical development plans.
  • “After thorough analysis and careful consideration, we are confident that focusing our resources toward NX-13’s clinical development has the potential to deliver the most value for Landos and our shareholders,” said Gregory Oakes, President and Chief Executive Officer of Landos.
  • “Our goal is to evolve Landos from a discovery-based organization into an immunology development powerhouse.
  • The Company will host a live webcast to provide a comprehensive update on Landos’ clinical development plans at 8:00 AM ET today.

Feinstein Institutes Researchers Discover a Molecule to Clear Invading Bacteria in Septic Patients

Retrieved on: 
Friday, January 6, 2023
Health, Biometrics, Other Health, General Health, Research, Science, Biotechnology, Immunosuppression, Feinstein Institute for Medical Research, Macrophage, Infection, Protein, Mouse, Bacteria, Medicine, Research, Septic, Death, Multimedia, Inflammation, Patient, Cytoskeleton, Radiation exposure, Foundation for the National Institutes of Health, Shock, Soft tissue injury, Immune system, Small intestinal bacterial overgrowth, RNA, Cell, Pharmaceutical industry, Vaccine, MD, Sepsis

(Credit Feinstein Institutes)

Key Points: 
  • (Credit Feinstein Institutes)
    The new study explores how extracellular cold-inducible RNA-binding protein (eCIRP) – an alarm molecule released during sepsis – causes immune dysfunction.
  • Specifically, eCIRP disrupts the cells within the immune system, which ingest bacteria and secrete both pro-inflammatory and antimicrobial mediators, known as macrophages.
  • “There is no single specific treatment for patients with sepsis and it remains an enigmatic disease for researchers globally,” said Dr. Wang, professor and chief scientific officer at the Feinstein Institutes.
  • “By reducing eCIRP molecules, we can lower the bacteria in septic patients and improve their outcome.

Yoomi and Rutgers Partner to Improve Physical Therapy Adherence Through Digital Health Platform

Retrieved on: 
Thursday, January 5, 2023
Health, Technology, Hospitals, Physical Therapy, Research, Artificial Intelligence, Science, Robert Wood Johnson Medical School, Associate, Journal, Assistant, Journal of Medical Internet Research, Executive, Physical, Health, Internal medicine, Division, Dallas Cowboys, Johnson & Johnson, Research, Patient, Varian Medical Systems, Rehabilitation, Code, Exercise, Entrepreneurship, GE Healthcare, Foundation for the National Institutes of Health, Rutgers University, RWJBarnabas Health, Medical school, RTM, NIH, High Point University, Pharmaceutical industry, MD, Geriatrics, Medicine, Yoomi Tamai

Yoomi, a digital health company focused on improving the standard of care in physical therapy, announced today it is partnering with Rutgers Robert Wood Johnson Medical School to explore how technology can mobilize patients effectively in physical therapy programs.

Key Points: 
  • Yoomi, a digital health company focused on improving the standard of care in physical therapy, announced today it is partnering with Rutgers Robert Wood Johnson Medical School to explore how technology can mobilize patients effectively in physical therapy programs.
  • “Patients who do not feel engaged with their physical therapy program are far less likely to adhere to it,” said Ben Catania, Co-Founder and CEO of Yoomi.
  • “Our platform can help to encourage patient engagement and provide critical exercise data for healthcare professionals to improve care.
  • Yoomi received awards and prize money from the National Institute of Health (NIH) and Johnson & Johnson for meeting an unmet need in healthcare.

Global mRNA Therapeutics Market Report 2022 to 2030 - Size, Share & Trends Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Genetics, Health, Therapy, National Institute of Allergy and Infectious Diseases, Heart, HIV, Infection, R, CVD, Foundation for the National Institutes of Health, Muscle tissue, Patient, COVID, Hospital, NIAID, Immunization, AstraZeneca, Incidence, Diabetes, Investment, COVID 19, COVID-19, Cell, RNA transfection, Vaccine, Clinical trial, Degenerative disease, Growth, COVID-19 vaccine, Arcturus Therapeutics, RNA, Pharmaceutical industry

The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

Key Points: 
  • The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.
  • With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications.
  • A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
  • As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug.

QT Imaging and GigCapital5 Announce Signing of Business Combination Agreement to Bring Breast and Full Body Imaging Solutions to the Public Markets

Retrieved on: 
Monday, December 12, 2022
Other Health, General Health, Professional Services, Radiology, Business, Oncology, Consumer, Health Technology, Other Professional Services, Women, FDA, Finance, Health, QT, Cancer, Telecommunication, Roman Catholic Diocese of La Crosse, Woman, Proxy, COVID-19, Foundation for the National Institutes of Health, Breast, Risk, LLP, Special-purpose acquisition company, IPO, NIH, Private, Life, MRI, Partnership, Sale, Radiation, NYSE, Multimedia, Failure, Partner, Security (finance), Person, Name, MD, Pregnancy, Form, Cryotherapy, SPAC, Acquisition, Federal Food, Drug, and Cosmetic Act, PPE, CT, DLA Piper, Communication, GIA, Annual report, Research, FDA, Compression, Prospectus, Finance, TMT, Mammography, CDC, 3D printing, Medical imaging

QT Imaging exists to provide an improved imaging modality to address critical deficiencies in the current breast imaging paradigm.

Key Points: 
  • QT Imaging exists to provide an improved imaging modality to address critical deficiencies in the current breast imaging paradigm.
  • QT Imagings core mission is to provide safe, highly accurate and inexpensive imaging systems to women and children, said John Klock, MD, Founder and CEO of QT Imaging.
  • The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patients breast.
  • This communication is being made in respect of the proposed business combination involving QT Imaging, GigCapital5 and GigCapital5s wholly-owned subsidiary, QTI Merger Sub, Inc.

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Retrieved on: 
Wednesday, December 7, 2022
Security (finance), Half-light: Collected Poems 1965–2016, Genetics, Culture, Development, Publishing, Science, McGraw, 2021 Essex County Council election, Patient, Prevalence, ClinVar, Foundation for the National Institutes of Health, Forensic Science International: Genetics, Research, Precision medicine, NYSE, Medicine, Genomics, Growth, Clinical trial, SAN, Database, Legislation, Genetic testing, Medical imaging, Pharmaceutical industry, Medical device, Invitae

SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Transparency and Impact Report, which details how the company has used de-identified patient data to advance precision medicine. While many companies collect patient data, they do not disclose how this data is being used. Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021. 

Key Points: 
  • While many companies collect patient data, they do not disclose how this data is being used.
  • Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021.
  • Unlike most companies, Invitae offers patients a choice on whether or not to allow access to their de-identified data for research.
  • Further showcasing the importance of sharing patient data, Invitae recently reached a milestone of more than 1 million ClinVar submissions .